Richard N. Kishner, M.D.

rkishner@smgumc.com

A board certified neurologist, with a special interest in Parkinson’s disease, movement, vestibular and balance disorders, headaches and cerebrovascular accidents.

PROFESSIONAL and TEACHING ACTIVITIES

[1982-present] Private Practice of Neurology: Fort Lauderdale, Florida

[1999-present] Medical Director, The Debby Sanderson National Parkinson’s’ Foundation Care Center

[present] Researcher for Neurological Associates

MEDICAL DEGREE

[1977] University of Witwatersrand, Johannesburg, South Africa

CERTIFICATIONS, QUALIFICATIONS AND APPOINTMENTS

Diplomate, American Board of Neurology

American Board of Psychiatry and Neurology

[1974] University of Witwatersrand, Johannesburg, South Africa, Bachelor of Science

GRADUATE TRAINING

Internship: General Medicine and Surgery

[1978] (Baragwanath Hospital, Johannesburg, South Africa. Departments of Medicine and Surgery.)

Residency: Psychiatry

[1979] (Johannesburg General Hospital, Johannesburg, South Africa.  Department of Psychiatry.)

Residency: Neurology

[1979-1982] (Bellevue Hospital, New York University, New York, Department of Neurology.)

AFFILIATED ASSOCIATIONS

American Academy of Neurology

BCMA

EMA

RESEARCH, PRESENTATIONS, PUBLISHED BOOKS AND PAPERS

[1997] Alberico, A., Kishner, R., and Hilsenbeck, Intrathecal Baclofen Therapy for Spasticity due to Stroke, A Clinical Case Study, Medtronic

Co-Investigator, Clinical Investigation of Deep Brain Stimulation for the treatment of Tremor using the  Medtronic Model 3382 DBS lead and Itrel II system.

[2000-2001] Teva Marion Partners, mc, Protocol PMO2, Indication-Multiple Sclerosis.

[2000-2001] Novartis Pharmaceuticals mc, Protocol CC0M998 U501, Indication-Parkinson’s Disease.

[2001-2004] Mylan Pharmaceuticals mc, Protocol APO4O1.02, Indication-Parkinson’s Disease.    

[2001-2004] Mylan Pharmaceuticals mc, Protocol AP0303, Indication-Parkinson’s Disease.

[2001-2004]Janssen Pharmaceuticals Inc, Protocol GAL-USA23, Indication-Parkinson’s Disease.